KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
Open Access
- 14 May 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (10) , 2565-2574
Abstract
Purpose: KTN0158 is a novel anti-KIT antibody that potently inhibits wild-type and mutant KIT. This study evaluated the safety, biologic activity, and pharmacokinetic/pharmacodynamics profile of KTN0158 in dogs with spontaneous mast cell tumors (MCT) as a prelude to human clinical applications. Experimental Design: Cell proliferation, KIT phosphorylation, and mast cell degranulation were evaluated in vitro. KTN0158 was administered to 4 research dogs to assess clinical effects and cutaneous mast cell numbers. Thirteen dogs with spontaneous MCT were enrolled into a prospective phase I dose-escalating open-label clinical study of KTN0158 evaluating 3 dose levels and 2 schedules and with weekly assessments for response and clinical toxicities. Results: KTN0158 was a potent inhibitor of human and dog KIT activation and blocked mast cell degranulation in vitro. In dogs, KTN0158 was well tolerated and reduced cutaneous mast cell numbers in a dose-dependent manner. Clinical benefit of KTN0158 administration in dogs with MCT (n = 5 partial response; n = 7 stable disease) was observed regardless of KIT mutation status, and decreased KIT phosphorylation was demonstrated in tumor samples. Histopathology after study completion demonstrated an absence of neoplastic cells in the primary tumors and/or metastatic lymph nodes from 4 dogs. Reversible hematologic and biochemical adverse events were observed at doses of 10 and 30 mg/kg. The MTD was established as 10 mg/kg. Conclusions: KTN0158 inhibits KIT phosphorylation, demonstrates an acceptable safety profile in dogs, and provides objective responses in canine MCT patients with and without activating KIT mutations, supporting future clinical evaluation of KTN0158 in people. Clin Cancer Res; 23(10); 2565–74. ©2016 AACR.Keywords
All Related Versions
Funding Information
- National Center for Advancing Translational Sciences (UL1TR001070)
- NCI (P30CA016058)
This publication has 45 references indexed in Scilit:
- Gene of the month:KITJournal of Clinical Pathology, 2015
- Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus documentVeterinary and Comparative Oncology, 2013
- Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell FactorCell, 2007
- Recent advances in the understanding of mastocytosis: the role of KIT mutations*British Journal of Haematology, 2007
- Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of PanitumumabThe Journal of Immunology, 2007
- Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomachInternational Journal of Oncology, 2006
- Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene MutationClinical Cancer Research, 2005
- Mast cell tumors in the dogVeterinary Clinics of North America: Small Animal Practice, 2003
- Cell Signaling by Receptor Tyrosine KinasesCell, 2000
- Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kitExperimental Hematology, 1999